The risk for central nervous system (CNS) involvement is small in cases of diffuse large B-cell lymphoma (DLBCL) because only about 5% of patients develop it. But certain high-risk patients are even ...

—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...

Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901 ...

Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network The study cohort included 27 ...

With little data available on outcomes among patients who have B-cell lymphoma (BCL) and secondary central nervous system (CNS) involvement who were administered CD19-targeting chimeric antigen ...

PMB-CT01, a BAFF-R targeting CAR-T cell therapy, achieved a 100% complete response rate in relapsed/refractory follicular lymphoma patients. The phase 1 PMB-102 study focuses on safety, optimal dosing ...